The study showed significant reductions in serum TTR levels in subjects after a single dose, with sustained effects over time ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a ...

The European Union health agency on Monday warned that Europe was set to miss goals on reducing the use of antibiotics, ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

(RTTNews) - Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), Monday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended ...

Statement/Regulatory AdmissionFormycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 ...

Despite their promise, these therapies have faced significant regulatory and access challenges. In July, the European ...

EMA encourages companies to submit type I variations for 2024 by end November 2024: Amsterdam, The Netherlands Monday, November 18, 2024, 14:00 Hrs [IST] European Medicines Agency ...

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...